Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2184637rdf:typepubmed:Citationlld:pubmed
pubmed-article:2184637lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0596382lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0043117lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0042672lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0439834lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:2184637lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:2184637pubmed:issue1lld:pubmed
pubmed-article:2184637pubmed:dateCreated1990-5-29lld:pubmed
pubmed-article:2184637pubmed:abstractTextThirty-eight patients with chronic refractory idiopathic thrombocytopenic purpura (ITP) were treated with weekly slow infusions of vincristine (0.02 to 0.04 mg/kg) or vinblastine (0.1 to 0.2 mg/kg). Twenty-two patients showed good to excellent responses after one to eight infusions. These responses were generally short, and lasted only in six patients after discontinuance of the therapy. The efficacy was comparable between vincristine and vinblastine. Neither the age, sex, duration of the disease, prior splenectomy nor combined use of adrenocortical steroids was likely to have influenced the therapeutic effect. Side effects such as peripheral neuropathy, alopecia, gastrointestinal symptoms and leukopenia occurred in 34 patients, and necessitated discontinuance of the therapy in eight patients. Slow infusions of vinca alkaloids can be an effective means of inducing platelet response in patients with chronic refractory ITP, but frequent side effects limit its clinical usefulness.lld:pubmed
pubmed-article:2184637pubmed:languageenglld:pubmed
pubmed-article:2184637pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2184637pubmed:citationSubsetIMlld:pubmed
pubmed-article:2184637pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2184637pubmed:statusMEDLINElld:pubmed
pubmed-article:2184637pubmed:monthFeblld:pubmed
pubmed-article:2184637pubmed:issn0001-5806lld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:MiuraYYlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:AbeTTlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:NomuraTTlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:BRUCKM AMAlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:MiyazakiTTlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:UchinoHHlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:NagaiKKlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:MaekawaTTlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:YawataYYlld:pubmed
pubmed-article:2184637pubmed:authorpubmed-author:KuriyaSSlld:pubmed
pubmed-article:2184637pubmed:issnTypePrintlld:pubmed
pubmed-article:2184637pubmed:volume53lld:pubmed
pubmed-article:2184637pubmed:ownerNLMlld:pubmed
pubmed-article:2184637pubmed:authorsCompleteNlld:pubmed
pubmed-article:2184637pubmed:pagination98-104lld:pubmed
pubmed-article:2184637pubmed:dateRevised2011-7-28lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:meshHeadingpubmed-meshheading:2184637-...lld:pubmed
pubmed-article:2184637pubmed:year1990lld:pubmed
pubmed-article:2184637pubmed:articleTitleClinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study.lld:pubmed
pubmed-article:2184637pubmed:affiliationThird Department of Internal Medicine, Nippon Medical School, Tokyo.lld:pubmed
pubmed-article:2184637pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2184637pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2184637pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:2184637pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:2184637pubmed:publicationTypeMulticenter Studylld:pubmed